Nursing Elites

1. When starting therapy with bicalutamide, a client should be instructed to monitor for which of the following adverse effects?

• A. Muscle pain
• B. Flushing
• C. Gynecomastia
• D. Hyperglycemia

Correct answer: C

Rationale: The correct answer is C: Gynecomastia. Bicalutamide, due to its antiandrogenic properties, can lead to gynecomastia in clients. This condition involves the development of breast tissue in males and is an important adverse effect to monitor when taking this medication. Choices A, B, and D are incorrect. Muscle pain and flushing are not commonly associated with bicalutamide use. Hyperglycemia is not a typical adverse effect of bicalutamide therapy.

2. A client starting highly active antiretroviral therapy (HAART) for HIV infection is being educated by a nurse on preventing medication resistance. What information should the nurse provide the client about resistance?

• A. Taking low dosages of antiretroviral medication minimizes resistance.
• B. Taking one antiretroviral medication at a time minimizes resistance.
• C. Taking medication at the same time daily without missing doses minimizes resistance.
• D. Changing the medication regimen when adverse effects occur minimizes resistance.

Correct answer: C

Rationale: To prevent the development of medication resistance, it is crucial for the client to take antiretroviral medication consistently at the same time daily without missing doses. This practice helps maintain effective drug levels in the body, reducing the risk of resistance development.

3. A client is receiving treatment with irinotecan. Which of the following findings should the nurse monitor?

• A. Diarrhea
• B. Hypertension
• C. Ototoxicity
• D. Neutropenia

Correct answer: A

Rationale: Corrected Rationale: Irinotecan is known to commonly cause diarrhea as an adverse effect due to its impact on the gastrointestinal tract. Therefore, the nurse should closely monitor the client for signs of diarrhea while receiving this treatment. Choices B, C, and D are incorrect because irinotecan is not typically associated with hypertension, ototoxicity, or neutropenia as primary adverse effects. While these side effects can occur with other medications, they are not the main concerns when monitoring a client receiving irinotecan.

4. A client is receiving moderate sedation with Diazepam IV and is oversedated. Which of the following medications should the nurse anticipate administering to this client?

• A. Ketamine
• B. Naltrexone
• C. Flumazenil
• D. Fluvoxamine

Correct answer: C

Rationale: Flumazenil is a competitive benzodiazepine antagonist that can reverse the sedative effects of benzodiazepines like Diazepam. In cases of oversedation, administering Flumazenil can help counteract the excessive sedation and other effects of Diazepam, thereby promoting the client's recovery and preventing potential complications. Ketamine (Choice A) is a dissociative anesthetic and not used to reverse benzodiazepine sedation. Naltrexone (Choice B) is an opioid receptor antagonist, not indicated for benzodiazepine oversedation. Fluvoxamine (Choice D) is an antidepressant and not used to reverse the sedative effects of benzodiazepines.

5. A client with breast cancer is being taught about Tamoxifen. Which of the following adverse effects of tamoxifen should the client be informed about?

• A. Irregular heart rhythm
• B. Abnormal uterine bleeding
• C. Yellowing of the sclera or dark-colored urine
• D. Difficulty swallowing

Correct answer: B

Rationale: Abnormal uterine bleeding is a known adverse effect of tamoxifen. It is important to educate the client about this side effect as those taking tamoxifen are at an increased risk for endometrial cancer. Any abnormal uterine bleeding should be promptly reported and evaluated by healthcare providers to ensure timely management and monitoring. The other options, such as irregular heart rhythm, yellowing of the sclera or dark-colored urine, and difficulty swallowing, are not typically associated with tamoxifen use and are not commonly reported adverse effects. Therefore, they are not the priority adverse effects to inform the client about.

Similar Questions